导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.34% | 2112/4773 |
| 近一周 | -1.92% | 890/5462 |
| 近一月 | -3.66% | 1892/5421 |
| 近一季 | -6.34% | 2053/5209 |
| 近半年 | -1.81% | 1697/4920 |
| 近一年 | 2.64% | 2076/4366 |
| 近两年 | 49.55% | 1475/2954 |
| 近三年 | 31.45% | 996/2253 |
| 成立以来 | 76.72% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.85% 2928/4961 |
12.88% 2100/5312 |
- - |
- - |
| 2025 | 20.66% 2101/4813 |
-0.55% 2301/3635 |
2.06% 1910/4076 |
18.37% 2309/4524 |
0.44% 1998/4813 |
| 2024 | 15.42% 933/3463 |
2.59% 749/2808 |
-1.30% 1027/3014 |
15.59% 1675/3129 |
-1.40% 1685/3463 |
| 2023 | -8.77% 1056/2656 |
3.81% 1122/2280 |
-4.56% 1202/2385 |
-2.45% 680/2515 |
-5.60% 1409/2655 |
| 2022 | -17.05% 547/2207 |
-13.57% 790/1919 |
7.47% 465/2016 |
-12.01% 630/2113 |
1.51% 1244/2208 |
| 2021 | 5.65% 541/1822 |
-2.40% 633/1255 |
8.71% 607/1330 |
-2.66% 588/1466 |
2.29% 629/1822 |
| 2020 | 43.26% 250/1250 |
-5.79% 438/1028 |
16.48% 436/1067 |
14.16% 296/1164 |
14.37% 282/1184 |
| 2019 | - - |
- - |
-1.22% 292/788 |
1.45% 400/850 |
7.50% 428/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 易方达MSCI中国A股联接C VS. 长安沪深300非周期A(740101) |